8-K: Annovis Bio Appoints Mark Guerin as New CFO

Annovis Bio, a late-stage clinical drug platform company, announced the appointment of Mark Guerin as its new Chief Financial Officer, effective September 25, 2025.

Summary

• Mark Guerin, age 57, has been appointed Chief Financial Officer of Annovis Bio, Inc., effective September 25, 2025.
• Mr. Guerin previously served as CFO of Onconova Therapeutics (now Traws Pharma, Inc.) from 2016 through February 2025, where he managed financial operations and critical financing transactions.
• His compensation package includes an annual base salary of $450,000, an annual target bonus of 40%, stock options to purchase 200,000 shares of common stock, six months severance pay, and participation in employee benefit plans.
• Annovis Bio is a late-stage clinical drug platform company focused on neurodegenerative diseases like Alzheimer's and Parkinson's disease.
• The company's lead drug candidate, buntanetap, continues to show promise in late-stage clinical development, having demonstrated efficacy in smaller trials and is on track for larger registrational studies.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced Chief Financial Officer with a strong track record in biopharma finance, particularly during a critical clinical development phase, is a significant positive for the company's operational and strategic capabilities. This strengthens management and signals preparation for future growth and potential commercialization.

Positives

• The appointment of Mark Guerin, an experienced financial executive with a strong track record in biopharma, is expected to strengthen Annovis Bio's financial leadership during a pivotal clinical development phase.
• Mr. Guerin's background includes managing financial operations, reporting, forecasting, internal controls, and completing several critical financing transactions for a publicly traded biopharma company.
• Annovis Bio's lead drug candidate, buntanetap, is progressing well in late-stage clinical development, having shown efficacy in smaller trials and is anticipated to replicate this success in larger registrational studies.

Risks

• Actual results may differ from forward-looking statements due to various risks and uncertainties, including those outlined in the company's SEC filings under Risk Factors in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
• The company undertakes no obligation to update forward-looking statements except as required by law.

Future Outlook

Annovis Bio anticipates that its lead drug candidate, buntanetap, will continue to demonstrate efficacy in larger, registrational clinical studies, building on its success in smaller trials, as the company aims to deliver a therapeutic solution for patients with neurodegenerative diseases.

Management Comments

• "I am very excited to join the Annovis team at this critical juncture for the company and for patients with neurodegenerative diseases, as buntanetap has demonstrated efficacy in smaller trials and is on track to replicate that success in larger, registrational clinical studies." Mark Guerin, CFO at Annovis.
• "I look forward to supporting the clinical success of buntanetap and to Annovis delivering a therapeutic solution for patients who need it most." Mark Guerin, CFO at Annovis.

Industry Context

The appointment of an experienced CFO with a strong biopharma background is a strategic move for Annovis Bio, a late-stage clinical drug platform company, as it navigates the complex and capital-intensive landscape of neurodegenerative disease drug development. This aligns with industry trends where companies in pivotal clinical phases often bolster their executive teams to manage financial operations, potential financing rounds, and prepare for commercialization.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are detailed in this filing to assess Annovis Bio's performance against global benchmarks.

Management Changes

Related Party Transactions

• There are no transactions of the type required to be disclosed pursuant to Item 404(a) of Regulation S-K between the Company and Mr. Guerin.

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO is generally viewed positively, potentially enhancing financial management, strategic planning, and investor confidence.
• Employees: A strengthened leadership team can provide clearer direction and stability.
• Patients: The new CFO's role in supporting the clinical success of buntanetap could indirectly benefit patients by facilitating the development and potential delivery of a therapeutic solution for neurodegenerative diseases.

Next Steps

• Continue late-stage clinical development of buntanetap for neurodegenerative diseases.
• Support the clinical success of buntanetap towards delivering a therapeutic solution for patients.

Key Dates

Recommendation

The appointment of Mark Guerin as CFO is a positive development, bringing significant financial and biopharma experience to Annovis Bio during a critical period of clinical development. This strengthens the management team and improves the company's operational capabilities. However, this is a management change and does not fundamentally alter the inherent risks or potential rewards associated with the company's drug development pipeline. While a positive signal, it does not immediately warrant a 'buy' or 'sell' recommendation without further clinical or financial updates. Therefore, a 'hold' recommendation is appropriate, acknowledging the improved management while awaiting more substantive news on clinical trials or financial performance.

Keywords

Annovis Bio, Mark Guerin, CFO appointment, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, buntanetap, clinical development, biopharma, financial executive